(HealthDay News) – Among patients with diabetes undergoing revascularization for multi-vessel coronary artery disease (CAD), coronary artery bypass graft (CABG) surgery provides better intermediate health status and quality of life (QOL) than percutaneous coronary intervention (PCI) with drug-eluting stents, but the differences are small and transient, according to research published in the Oct. 16 issue of the Journal of the American Medical Association.

Mouin S. Abdallah, MD, of Saint Luke’s Mid America Heart Institute in Kansas City, MO, and colleagues assessed the effects of CABG (947 patients) vs. PCI (953 patients) on health status and QOL in patients with diabetes and multi-vessel CAD.

At two-year follow-up, the researchers observed significantly greater mean differences in treatment benefit in scores for angina frequency (1.3 points), physical limitations (4.4 points), and QOL subscales (2.2 points) with CABG vs. PCI. After two years, patient outcomes were similar in both groups.

“Beyond two years, there were no consistent differences in any health status or quality-of-life domains between the CABG and PCI strategies,” the authors write.

Several authors disclosed financial ties to the pharmaceutical and/or medical device industry, which provided funding, study drugs, and stents.

Full Text (subscription or payment may be required)